Giza, Egypt

Abdelrahman S Mayhoub

USPTO Granted Patents = 3 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2016-2019

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations by Abdelrahman S Mayhoub

Introduction

Abdelrahman S Mayhoub is a notable inventor based in Giza, Egypt. He has made significant contributions to the field of antimicrobial research, particularly in the development of therapeutic agents for bacterial infections. With a total of three patents to his name, his work is recognized for its potential impact on public health.

Latest Patents

One of his latest patents is titled "Phenylthiazoles and uses thereof." This patent discloses a series of 2-phenyl-4-methylthiazole analogs that are potential therapeutic agents for the treatment of bacterial infections, especially those related to methicillin-resistant Staphylococcus aureus (MRSA). Additionally, he has claimed a method for the treatment of MRSA-related infections. Another significant patent is "Antimicrobial substituted thiazoles and methods of use," which reveals compositions that exhibit activity against MRSA and/or vancomycin-resistant Staphylococcus aureus (VRSA). This patent also outlines methods for using these compositions to treat microbial infections.

Career Highlights

Abdelrahman S Mayhoub is affiliated with the Purdue Research Foundation, where he continues to advance his research in antimicrobial agents. His work is characterized by a strong focus on addressing the challenges posed by antibiotic-resistant bacteria.

Collaborations

He has collaborated with notable colleagues in his field, including Mark Stanley Cushman and Mohamed Seleem. These collaborations have contributed to the development of innovative solutions in antimicrobial research.

Conclusion

Abdelrahman S Mayhoub's contributions to the field of antimicrobial research through his patents and collaborations highlight his commitment to addressing critical health challenges. His work continues to pave the way for new therapeutic options in the fight against resistant bacterial infections.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…